John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

After more than a decade of dog treats and deliveries, a UPS driver in Georgia shared an emotional moment with a couple of pups and their owner as he bid them farewell during his last shift. This ...

Toyota Camry SE AWD Interior Design in Black ...

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development ; Hummingbird Bioscience stands to receive ...

Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

“This is for sure going to work,” Surge Biswas, PhD, CEO of Nabla Bio, told me when asked to weigh in on the future outlook of de novo antibody design, or designing antibodies not found in nature.

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims ...

Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 ...